A pilot simulation study published in the journal Nature Medicine analyzed data from 174,678 patients with type 1 diabetes and found that initiation of glucagon-like peptide-1 receptor agonists (GLP-1RA) was associated with a reduced risk of major cardiovascular events. The study also showed that GLP-1RAs reduce the risk of end-stage renal disease in patients with type 1 diabetes. The research used data from electronic medical records, which enabled the analysis of a large number of patients in real clinical practice. These findings expand knowledge about the benefits of GLP-1RAs, which until now have primarily been studied in patients with type 2 diabetes. The results suggest that GLP-1RAs may have cardiovascular and renal protective effects even in patients with type 1 diabetes. The study thus provides important evidence for the potential expansion of the use of GLP-1RA in the treatment of type 1 diabetes.